In addition it has been shown that VEGF levels are significantly increased in uveal melanoma patients with metastatic disease as compared to patients without metastases, therefore using anti-angiogenic therapies might be potentially beneficial for the treatment of primary uveal melanoma or metastatic disease [47]. The gene discussed is VEGFA; the disease is metastatic neoplasm.